San Francisco startup Framework Therapeutics is additionally engaged on an oral, after-day-to-day GLP-1 drug identified as GSBR-1290—the drug surpassed Wall Avenue’s anticipations in June whenever a mid-phase examine confirmed average weight loss of all over six% and it strategies to